Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Voluntarily Recalls Picillibacta IV Inj. 1.5 g
January 11, 2013
- Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
- Janssen Resumes Supply of Doxil
January 10, 2013
- Daiichi Sankyo to Jointly Develop Autoimmune Disease Therapy with Amplimmune
January 10, 2013
- Top Officials of Major Drug Makers Express Concerns Mixed with Some Understanding About New Pricing Rule for Long-Listed Drugs
January 10, 2013
- BI, Eli Lilly Plan to Submit SGLT-2 Inhibitor Empagliflozin for Approval in Japan, US, and Europe in 2013
January 10, 2013
- Novartis Launches Respiratory Infection Treatment Tobi
January 10, 2013
- Chugai Licenses Novel Anticancer Agent FF284 to Debiopharm of Switzerland
January 10, 2013
- Pharmaceutical Firms’ Leaders Hopeful of New Products and Determined to Build Stronger Business Foundations
January 9, 2013
- AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
- Sanofi Transfers Marketing Rights from Genzyme for Fludara
January 9, 2013
- Ajinomoto Pharmaceuticals Launches Atelec in Vietnam
January 9, 2013
- Novartis Pharma and Eisai Terminate Copromotion Agreement for COPD Therapies
January 9, 2013
- Bayer Yakuhin Files Eylea for Macular Edema Associated with CRVO
January 9, 2013
- Japan Should Invest More in Whole Genome Sequencing and Interpretation of Cancer-related Genomic Abnormalities: Dr Nakagawa of RIKEN
January 9, 2013
- BONAC Offers Solutions to Overcome Difficulties Faced in Development of Nucleic Acid Medicines: Managing Director Mizutani
January 9, 2013
- Nippon Kayaku Ups FY2012 Outlook for Pharma Biz, Anticancer Generics Brisk
January 8, 2013
- Abbott Japan’s Spin-Off AbbVie G.K. Starts Operations in January with CEO Winer
January 8, 2013
- “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
- Sanofi K.K. Acquires DPP-4, SGLT-2 Inhibitors from Novartis, Chugai Aiming for Growth of Its Own Major Products for Diabetes through Synergism
January 7, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…